GLMD•benzinga•
Galmed Announces Part 1 Results From AM-001 Study Of Aramchol Meglumine, An Enhanced Formulation Of The Most Clinically Advanced SCD1 Inhibitor
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 10, 2025 by benzinga